Abstract Body

In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus yeast clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint. The US FDA allows for surrogate endpoints for accelerated regulatory approval, but there are no accepted surrogate endpoints for this neglected disease. For tuberculosis, the FDA recognizes an official surrogate endpoint as “time to sputum culture conversion to negative.” We examined the relationship between the rate of CSF Cryptococcus clearance (i.e. EFA) and mortality through 18 weeks.

We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted in Uganda during 2010-2013 (COAT trial, n=162; also in South Africa), 2013-2014 (ASTRO-CM pilot, n=179), and 2015-2019 (ASTRO-CM trial, n=397). All subjects received amphotericin B deoxycholate + fluconazole induction therapy and had serial quantitative CSF cultures performed. The log10 transformed colony forming units (CFUs) per mL CSF were analyzed by general linear regression vs day of CSF culture over the first 10 days. The slope of the fit line is the EFA or the rate of CSF fungal clearance in units of log10CFU/mL/day. We grouped subjects by EFA and compared mortality by Kaplan-Meier.

738 subjects had non-sterile initial cultures with a calculable EFA (median 0.38; IQR, 0.20-0.57 log10 CFU/mL). Risk of death through 18-weeks was higher with EFA <0.20 (50% mortality) versus EFA >=0.20 log10CFU/ml/day (37% mortality; Hazard Ratio 1.60; 95%CI, 1.25 to 2.04; P=0.002). Mortality through 18-weeks was 37% for EFA ≥0.60 (n=170), 36% for EFA 0.40-0.59 (n=182), 39% for EFA 0.30-0.39 (n=112), and 35% for EFA 0.2-0.29 (n=87). When adjusting for baseline Glasgow coma scale, hemoglobin, CSF quantitative culture, CSF WBC, biological sex, and cohort, EFA remained significant (adjusted Hazard Ratio 1.83, 95%CI, 1.40 to 2.40; P<0.0001).

EFA was associated with all-cause mortality using individual level data from 738 subjects receiving amphotericin-combination induction therapy. An EFA better than 0.20 log10 CFU/mL/day was associated with similar survival, and this threshold may be considered a target for a surrogate endpoint. Yet, 25% of patients receiving amphotericin had EFAs worse than 0.20 log10CFU/mL/day, with 50% mortality. This builds upon prior systematic reviews of smaller pooled studies from different sites to validate EFA as a surrogate endpoint.